Empagliflozin in patients with heart failure and reduced ejection fraction

Background: Sodium–Glucose Cotransporter 2 (SGLT2) inhibitors reduce the risk of a first null hospitalization for heart failure in type 2 diabetics. But data regarding role of SGLT2 inhibitors in null HFrEF is limited. Methods: In this prospective small centre trial, we randomly assigned 822 patients in class II, III, null NYHA and an ejection fraction of 35% or less to receive either empagliflozin or placebo, in addition null to...